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ZO (zonula occludens) proteins are scaﬀolding proteins providing the structural basis for the assembly of multiprotein complexes
at the cytoplasmic surface of intercellular junctions. In addition, they provide a link between the integral membrane proteins and
the ﬁlamentous cytoskeleton. ZO proteins belong to the large family of membrane-associated guanylate kinase (MAGUK)-like
proteins comprising a number of subfamilies based on domain content and sequence similarity. Besides their structural function
at cell-cell contacts, ZO proteins appear to participate in the regulation of cell growth and proliferation. Detailed molecular studies
have shown that ZO proteins exhibit conserved functional nuclear localization and nuclear export motifs within their amino
acid sequence. Further, ZO proteins interact with dual residency proteins localizing to the plasma membrane and the nucleus.
Although the nuclear targeting of ZO proteins has well been described, many questions concerning the biological signiﬁcance of
this process have remained open. This review focuses on the dual role of ZO proteins, being indispensable structural components
at the junctional site and functioning in signal transduction pathways related to gene expression and cell behavior.
1.Introduction
Epithelial and endothelial cells attach to each other by
various occluding junctions which rely on the function of
speciﬁc proteins characterized by common structural fea-
tures, that is, one or more transmembrane domains ﬂanked
by cytoplasmic and extracellular portions. Accumulating
experimental evidence has suggested that protein-protein
interactions at the cytoplasmic region(s) of such trans-
membrane junctional proteins modulate the extracellular
action of the protein which accomplishes homophilic or
heterophilic binding to extracellular domains of junctional
proteins of neighbouring cells. In this way, a regulatable
intercellular seal is created.
Zonula occludens (ZO) proteins, comprising ZO-1, -2,
and -3, are peripheral proteins localizing at junctional sites.
ZO proteins are scaﬀolding proteins recruiting various types
of proteins to the cytoplasmic surface of the junction,
therebycontributingtothesocalled“junctionalplaque”. ZO
proteinshaveoriginallybeendescribedtolocalizespeciﬁcally
totightjunctions(TJs)(zonulaeoccludentes)[1,2].However,
this notion was quickly reevaluated, since these proteins
were found to associate with the cadherin-based adherens
junctions (AJs) in cells lacking TJs [3]. Moreover, ZO
proteins also associate with gap junctions (GJs) by directly
interacting with connexins [4–6], which points towards a
general role of ZO proteins in intercellular adhesion and
communication.
ZO proteins carry some domains required for struc-
tural organization of intercellular junctions and additional
domains capable of functioning in signal transduction
pathways. The most prominent function of ZO proteins at
thejunctionalsiteistheregulationofclaudinpolymerization
inepithelialcells,whichwasdemonstratedbyuseofareverse
genetic approach [7].
In recent years, intriguing evidence has accumulated
suggesting that ZO proteins not only exert functions related
to structural barrier mechanisms but are also involved in
signal transduction and transcriptional modulation.
ZOproteins interactdirectlywithmost ofthetransmem-
brane proteins localizing at TJs, such as occludin, claudins,
JAM (Junctional adhesion molecule), tricellulin, and CAR
(coxsackievirus and adenovirus receptor) [8–14]( Figure 1).
Their association with AJs is accomplished through
binding to alpha-catenin [14, 15] and members of the p120
catenin family [14–17] as well as to the nectin-interacting2 Journal of Biomedicine and Biotechnology
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Figure 1: Localization of zonula occludens (ZO) proteins at tight junctions (TJs). Transmembrane components of TJs interact at least with
oneZOprotein.Asmentionedinthetext,onlyZO-1andZO-2localizetothenucleus,whilenucleartargetingofZO-3hasnotbeenobserved
so far. Already described interactions of ZO proteins with other types of junctions is not included here. TJs: tight junctions; AJs: adherens
junctions; DM: desmosomes; GJs: gap junctions; CAR: coxsackievirus and adenovirus receptor.
protein AF-6 (ALL-1 fusion partner at chromosome 6)/
afadin [18]. This somehow reﬂects the canonical role of ZO
proteins, which is to establish a link between the transmem-
brane components and the perijunctional cytoskeleton at
cell-cell contacts [19–21]. In addition, ZO proteins interact
with a series of cytoplasmic proteins, including adapters, sig-
naling molecules and transcriptional regulators [22–27] sug-
gesting a novel function of ZO proteins, far beyond their role
as indispensable structural components at the junction site.
2. ZO ProteinsAreMAGUK Proteins
ZO proteins belong to the large family of membrane-
associatedguanylatekinase(MAGUK)likeproteins.Theﬁrst
MAGUKproteindentiﬁedwastheproductoftheDrosophila
tumor suppressor gene lethal(1)discs-large (dlg). Loss-of-
function mutations in dlg lead to the tumorous overgrowth
of imaginal discs of Drosophila larvae [28, 29].
MAGUKs are scaﬀolding proteins which create and
maintain multimolecular complexes at distinct subcellu-
lar sites, such as the cytoplasmic surface of the plasma
membrane [30, 31]. By means of multiple protein bind-
ing domains, they bring together cell adhesion molecules,
cytoskeletal proteins, receptors, ion channels and additional
signaling components. Thereby, protein-protein interac-
tion is accomplished by small modular domains, such as
Src-homology3 (SH3) domains, phosphotyrosine-binding
domains (PTB), or PDZ domains [30]. In spite of their
similardomainstructure,MAGUKsaredistinctiveenoughto
be classiﬁed into seven subfamilies based on domain content
and sequence similarity [32].
Junctional MAGUKs belong to the dlg-like and ZO-
1-like subgroups of MAGUKs. They are characterized by
one or more copies of PDZ (PSD-95/discs large/zonula
occludens-1) domains, an SH3 (Src Homology 3) domain,
and a region homologous to mammalian and yeast cytosolic
guanylate kinase (GUK) (from N- to C-terminus). Similar
to other MAGUKS, a number of highly variable regions
are located between the conserved domains. The best
studied variable region is the HOOK domain, a basic hinge
region between the SH3 and GUK domain, involved in
regulating ligand binding and oligomerization of MAGUKs
[33, 34]
2.1. PDZ Domain. Although originally identiﬁed in meta-
zoans, PDZ domains have been found to be spread through
bacteria, fungi and plant lineages as well [35, 36]. PDZ
domains (80–100 amino acid residues) play a key role in
cellular signaling. They either form dimers or bind to C-
terminal regions of integral membrane and intracellular
proteins. PDZ is an acronym, combining the ﬁrst letters
of three proteins which were ﬁrst discovered to share the
domain: The post synaptic density protein (PSD95/SAP90),
the Drosophila septate junction protein Discs-large (DlgA),
and the epithelial tight junction protein zonula occludens-
1 (ZO-1). PDZ domains are sometimes referred to as DHR
(Dlg homologous region) or GLGF (glycine-leucine-glycine-
phenylalanine) domains [36].Journal of Biomedicine and Biotechnology 3
PDZ containing proteins are generally restricted to
speciﬁc subcellular domains, such as regions of cell-cell
contact in epithelial cells, the plasma membrane of red blood
cells and lymphocytes, and synaptic and neuromuscular
junctions [37]. The majority of PDZ containing proteins
is associated with the plasma membrane enabling the
creation of higher molecular structures [38]. Such structures
are mainly involved in intracellular signaling, cell adhe-
sion, ion transport, and the formation of the paracellular
barriers.
2.2. SH3 Domain. The Src homology 3 domain is a small
protein domain of about 60 amino acid residues present
in a large number of intracellular or membrane-associated
proteins [39]. It was ﬁrst identiﬁed as a conserved sequence
in the viral adaptor protein c-Crk and the non-catalytic parts
of enzymes such as phospholipase and several cytoplasmic
tyrosine kinases [39]. SH3 domains are found in proteins
that are involved in signaling pathways regulating the
cytoskeleton, the Ras protein, and the Src kinase and many
others. By binding to proline-rich ligands, these domains
play critical roles in a wide variety of biological processes
ranging from regulation of enzymes by intramolecular inter-
actions, altering the subcellular localization of components
of signaling pathways, and mediating the assembly of large
multi-protein complexes [40].
2.3. GUK Domain. GUK (guanylate kinase) domains exhibit
sequencesimilaritytoguanylatekinase,whichconvertsGMP
to GDP using ATPase as a phosphate donor. Some members
of the MAGUK family, such as p55-like and Lin-2-like
MAGUKs, have intact GMP binding and ATP-binding sites,
while ZO-1-like MAGUKs lack several residues predicted to
bindGMP[34,41].Interestingly,usingphylogeneticanalyses
and molecular modelling it was demonstrated that the
MAGUK GUK domain originated from a catalytically active
GK domain and gradually lost its enzymatic characteristics
when new subfamilies emerged [32]. Several studies suggest
that the GUK domain of MAGUK proteins has evolved as a
protein-protein interaction domain. A number of vertebrate
GUK domain binding partners, including the microtubule-
associated protein MAP1A [42], the brain-enriched guany-
late kinase-associated protein (BEGAIN) [43], and the
kinesin-like protein GAKIN [44] have been identiﬁed so far.
In addition, the MAGUK GUK domain was suggested to
interact intramolecularly with the SH3 domain [41, 45].
3. StructuralandFunctional
Properties of ZO Proteins
The molecular structure and functions of ZO proteins have
extensively been described in a series of comprehensive
reviews that appeared during the last couple of years [19, 22,
24, 27, 31, 46–48]. Therefore, only a short outline of major
characteristics of ZO proteins is given here.
ZO proteins carry three PDZ domains, one SH3 domain,
aGUKdomainandaproline-richregionlocatedeitheratthe
C-terminus (ZO-1, ZO-2) or between the second and third
PDZ domain (ZO-3) [31]. The variable domains, termed
U(unique)1 to U6 are located between the core domains
of the ZO proteins (U5 is also referred to as “HOOK”
domain) [49]. The SH3-U5-GUK-U6 region of ZO-1 turned
out to be of particular importance for TJ assembly and
localization [49]. The U5 motif, which is found in several
MAGUKs, though without sequence homology, is required
for localization of ZO-1 to TJs in vivo and for binding of
ZO-1 to occludin in vitro. In contrast, the U6 motif, a short
sequenceﬂankingtheGUKdomain,isuniquetoZOproteins
and was found to inhibit binding of ZO-1 to occludin
in vitro [49]. Expression of a modiﬁed ZO-1, lacking U6,
induces ectopic strands consisting of occludin and claudins
but lacking most of the cytoplasmic plaque proteins [49]. As
in other MAGUKS, the SH3 and GUK domain of ZO-1 form
a hairpin loop through intramolecular interaction which
could determine the position of the U5 and U6 motifs and
thereby modulate the binding capacity of ZO-1 to occludin
a n dt oo t h e rp r o t e i n s[ 49].
The ﬁrst ZO protein identiﬁed was ZO-1, with a
molecular mass of 220 kD [2], which was discovered as an
antigen for a monoclonal antibody raised against a junction-
enriched fraction from liver tissue. ZO-1 associates with ZO-
2, a 160 kD protein [50, 51] and the 130 kD protein ZO-3
[52]throughbindingoftheircorrespondingPDZ-2domains
[53].
Interaction of ZO-1 with the C-termini of claudins was
found to be accomplished through PDZ-1 [10], while JAM
(Junction adhesion molecule) and occludin are contacted
by PDZ 2/3 [9] and a region localized at the SH3-hinge-
GUK domain, respectively [13, 49]( Figure 2). As mentioned
above, the unique motif located in this variable region
(termed U5) seems to be indispensable for binding of ZO-
1 to occludin [49]. Interaction with claudins via their ﬁrst
PDZ domain is a redundant function of all ZO proteins and
thus appears to be crucial for the formation and function of
TJs. Indeed, Umeda et al. [7] have demonstrated that ZO-1
andZO-2areindispensablefordeterminingwhenandwhere
claudins are polymerized.
ZO proteins associate with a series of peripheral junc-
tional proteins thereby creating a complex intracellular
network (Figure 2). Peripheral junctional proteins include
actin-and myosin binding proteins, signalling molecules
and transcriptional regulators. In addition, all ZO proteins
interact directly with actin ﬁlaments either via their COOH
terminal regions (ZO-1, ZO-2) or through a binding domain
located in the N-terminal half (ZO-3) which emphasizes
their role as cross linkers between TJ strands and the
cytoskeleton [54–56]. The importance of the perijunctional
actomyosin in ZO protein-mediated barrier formation was
reported recently by Van Itallie et al. [21].
The indirect interaction of ZO proteins with the
cytoskeleton involves several actin-binding proteins includ-
ing cortactin [57], alpha-catenin [11], protein 4.1R [58],
the Ras target AF6/afadin as well as the actin- and myosin-
binding proteins cingulin [59]a n dS h r o o m[ 60].
Signalling proteins associating with ZO-proteins include
the serin protein kinase ZAK (ZO-1 associated kinase-1)
which binds to the SH3 domain of ZO-1 and phosphorylates4 Journal of Biomedicine and Biotechnology
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Figure 2: ZO proteins interact with transmembrane proteins and with peripheral cytoplasmic proteins at the junctional site. Details are
mentioned in the text. Some proteins interacting with ZO proteins are not included in the ﬁgure since their association domain is less
well described. These include CAR (coxsackievirus and adenovirus receptor), tricellulin, and cingulin. ABR: actin binding region; AF-6:
ALL-1 fusion partner at chromosome 6; Apg-2: (ATP and peptide-binding protein in germ cells)-2; Cx: Connexin; Ga12: G protein α 12
subunit; GUK: Guanylate kinase-like domain; JAM: Junction adhesion molecule; hScrib: human Scribble; PATJ: Protein associated with
tight junctions; P-P-P: Proline-rich region; PDZ: Psd95/discs large/zonula occludens-1 domain; SAF-B: Scaﬀold attachment factor-B; SH3:
Src homology3 domain; U1-U6: Unique variable domains; ZAK: ZO-1 associated kinase; ZONAB: ZO-1 associated nucleic acid binding
protein; ZU5: Domain present in ZO-1 and Unc5-like netrin receptors.
a region immediately C-terminal to this domain [61]a n da
Gp r o t e i nα subunit (Gα12) which also associates directly
with the SH3 domain of ZO-1 [62]. Interaction of p120
catenin with a C-teminal domain of ZO-3 provides an
additional link to Rho signalling [17, 63]. Signalling at TJs
has comprehensively been reviewed recently [64] and is not
being dealt with further in this review.
Interaction of ZO-3 with the polarity protein PATJ
(protein associated with tight junctions) was suggested to
be important for the recruitment of PATJ and its associated
proteins to tight junctions [65]. Finally, ZO-2 interacts
directly with human Scribble (the human homologue of
the Drosophila tumor suppressor Scribble) which was shown
to be a substrate of high-risk human papillomavirus E6
oncoproteins for ubiquitin-mediated degradation [66].
The idea of a “dual function” of ZO proteins has
emerged from observations that ZO proteins interact with
proteinsinvolvedincellcycleprogressionandtranscriptional
regulation [67]. The nuclear targeting of ZO proteins
and their association with regulatory proteins participat-
ing in gene expression will be discussed in a following
chapter.
4. Loss of Function Mutationsof ZO Proteins
In order to gain more insight into the functional sig-
niﬁcance of ZO proteins in embryonic development and
tissue diﬀerentiation, a series of loss-of-function mutations
were analysed. Eph4 cells lacking ZO-1 show a retarded
recruitment of claudins and occludin to TJs, and delayed
barrier establishment [68]. Similar results were obtained by
McNeil et al. [69] showing that knockdown of ZO-1 in
MDCK cells retarded TJ formation by 3 hours. Interestingly,
mature junctions seemed to be unaﬀected even in the
persisting absence of ZO-1. Epithelial cells deﬁcient in both
ZO-1 and ZO-2 were well polarized but did not form TJs due
to the lack of claudin polymerization [7].
Knockout of ZO-1 was shown to be lethal for mouse
embryos around mid gestation [70]. No viable embryos
lacking ZO-1 were found beyond E11.5. Disturbed yolk
sac angiogenesis and delayed embryonic growth from E8.5
onwards were the most characteristic features of ZO-1 −/−
mice. In addition, massive apoptosis in the notochord, in
the neural tube area, and in the allantois at E9.5 was
described. Interestingly, deﬁciency of ZO-1 did not exert anyJournal of Biomedicine and Biotechnology 5
eﬀects on the localization of ZO-2/ZO-3 at junctional sites
but did induce mislocalization of endothelial JAMs in the
yolk sac, which might explain the disturbance of vascular
development.
Results from ZO-2 targeting experiments are somehow
controversial. Knockdown of ZO-2 using siRNA had no
discernible eﬀects on TJ structure or function in Eph48
cells, while in MDCK cells, the downregulation of ZO-
2 yielded a distinct TJ-related phenotype [71]. This was
reﬂectedbychangesinthegatefunctionofTJs(i.e.,increased
paracellular permeability and low transepithelial electrical
resistance)aswellasalterationsinthefencefunctionofTJsas
evidenced by a non-polarized distribution of E-cadherin. In
addition,delayedarrivalofZO-1,occludinandE-cadherinat
newly formed junctions following Ca++-switch wasobserved.
Mouse embryos lacking ZO-2 die shortly after implan-
tation due to an arrest in early gastrulation and disturbed
mesodermal diﬀerentiation. In addition, decreased prolifer-
ation at embryonic day 6.5 (E6.5) and increased apoptosis
at E7.5 together with elevated paracellular permeability of
a low-molecular-weight tracer was observed in ZO-2−/−
embryos [72]. A critical role of ZO-2 for the blood-testis
barrier was demonstrated recently by Xu et al. showing that a
lack of ZO-2 caused a disturbed blood-testis barrier and lead
to reduced fertility of chimeric mice [73].
Neither ZO-3 deﬁcient cells nor mouse embryos lacking
ZO-3 showed an apparent phenotype, suggesting that ZO-3
is not an indispensable component of TJs and might well be
substituted by one of the other ZO proteins [72, 74].
5. Nuclear Shuttlingof ZO Proteins
Besides their characteristic protein domains ZO proteins
exhibit several nuclear localization (NLS) and nuclear export
signals (NES) enabling them to shuttle between the cyto-
plasm and the nucleus [75–78].
A ﬁrst indication that a member of the ZO proteins
localizes to the nucleus came from Gottardi et al., [79]
showing that ZO-1 targets for the nucleus of subconﬂuent
epithelial cells before maturation of TJs. Gonzalez-Mariscal
and her group demonstrated that the nuclear localization
of ZO-2 is particularly dependent on the state of cell cell
contacts in epithelial monolayers [76]. Particularly in sparse
cultures, ZO-2 was found to localize at the nucleus but
gradually exits the nucleus in a leptomycin-sensitive way as
soon as the monolayer reaches conﬂuence. Transient nuclear
expression of ZO-2 in cerebral endothelial cells and kidney
epithelialcellswasalsoobservedbyTrawegeretal.[78].ZO-2
wasfoundtocolocalizepartiallywiththepre-mRNAsplicing
factor SC-35 and to coprecipitate with laminB1 and actin
from nuclei of sparse cultures [76].
Following heat shock and chemical insult increased
nuclear accumulation of ZO-2 was visible in epithelial and
endothelial cells [78]. Further, nuclear localization could be
induced by impairing cell-cell contacts by mechanical injury
(wounding) [76]. This suggests that nuclear accumulation of
ZO-2 is a general response of epithelial and endothelial cells
to environmental or mechanical stress.
6. Nuclear Actions of ZO Proteins
Although the dual localization (cytoplasmic/nuclear) of ZO
proteins is well documented, the biological signiﬁcance
of their nuclear targeting has long remained elusive. ZO
proteins interact with nuclear proteins as well as with
dual residency (cytoplasmic/nuclear) proteins (Figures 3(a)
and 3(b)) suggested to be involved in cell growth and
proliferation.
By using a yeast-based Two Hybrid screen and co-
immunoprecipitation, it was shown that nuclear ZO-2
interacts directly with the hnRNP protein SAF-B (scaﬀold
attachment factor-B) via its PDZ-1 domain [78]. SAF-
B/HET (Hsp27-ERE-TATA-binding protein) is a component
of chromatin and is expressed in all tissues investigated so
far. Originally, SAF-B/HET has been described as one of
the abundant nuclear proteins that function in chromatin
structure by interacting with scaﬀold or matrix attachment
DNA elements (S/MAR elements). In many cases, these
elements co-map with boundaries of actively transcribed
domains and have therefore been considered to exert regula-
tory eﬀects on adjacent genes [80]. SAF-B/HET was shown
to be highly concentrated in nuclear speckles colocalizing
with SC-35 and to directly interact with various splicing
factorsandRNApolymeraseII[81].Inaddition,SAF-B/HET
acts as a co-repressor of estrogen receptor alpha and SAF-
B/HET levels were found to be inversely correlated with
cell proliferation of breast cancer cells [82]. SAF-B/HET is
a suppressor of the small heat shock protein 27 (hsp27)
which enhances growth and proliferation of breast cancer
cells and turned out to be a bad prognostic marker in certain
subsets of breast cancer patients in breast carcinoma cells
[83].
Further evidence to suggest direct involvement of ZO-2
in cell growth and proliferation came from Huerta et al. [84]
demonstrating that ZO-2 modulates the expression of cyclin
D1 (CD1) through interaction with the transcription factor
Myc and subsequent binding to an enhancer box element of
the CD1 promoter. In this way, ZO-2 downregulates tran-
scription of CD1 and, in due course, suppresses proliferation
of cultured epithelial cells. In addition, ZO-2 downregulates
proteinsynthesisofCD-1andincreasesitsdegradationatthe
proteasome complex [85].
Convincing experimental evidence to suggest the critical
involvement of ZO proteins in epithelial cell proliferation
came from Balda et al. [86, 87] and Sourisseau et al.
[88] showing that ZO-1 interacts with the Y-box transcrip-
tion factor ZONAB (ZO-1 associated nucleic acid binding
protein), also referred to as DbpA/Msy3 (DNA binding
proteinA/Mouse Y box protein3), which in turn binds to
promoter regions of CD1 and PCNA (proliferating cell
nuclear antigen), an eukaryotic DNA replication factor,
thereby increasing their transcription. ZONAB is a dual
residency protein localizing at TJs and/or in the nucleus,
depending on the cells’ proliferative state and on the amount
of ZO-1 present at cell-cell contact sites. In conﬂuent
epithelial monolayers, ZONAB is bound to junctional ZO-
1. If ZO-1 is absent from junctional sites, ZONAB shuttles to
the nucleus while overexpression of junctional ZO-1 causes6 Journal of Biomedicine and Biotechnology
ZONAB (ZO-1)
Symplekin (ZONAB /ZO-1)
Cdk4 (ZONAB /ZO-1)
Jun, Fos, C/EBP (ZO-2)
ARVCF (ZO-1,ZO-2)
P120 catenin (ZO-3)
P
l
a
s
m
a
m
e
m
b
r
a
n
e
(a)
Nuclear Scaﬀold
SAF-B
ZO-2
ZO-1
ARVCF
ZO-2
Fos
Jun
C/EBP
ZO-2 CD-1
c-myc
LaminB1
SC35
(b)
Figure 3: (a) Summary of “dual residency proteins” (locating at the plasma membrane and at the nucleus) associating with ZO-proteins at
thejunctional site. (b) Nuclear interactions ofZO proteins.ZONAB:ZO-1 associated nucleic acid binding protein;Cdk-4:Cyclin-dependent
kinase-4; ARVCF: Armadillo repeat gene deleted in velo-cardio-facial syndrome; SC35: Splicing factor 35.
a redistribution of ZONAB from the nucleus to the cyto-
plasm. Another way, how ZONAB regulates epithelial cell
proliferationandcellcycleprogressionisthroughassociation
with the cyclin-dependent kinase-4 (Cdk4) which interacts
and colocalizes with ZONAB at TJs. In this way, Cdk4 is
prevented from entering the nucleus and participating in cell
cycle progression [86].
The small heat shock protein Apg-2 was shown to
regulate ZONAB function by competing for binding to the
SH3 domain of ZO-1 [89]
In addition, ZONAB forms a stable complex with sym-
plekin, a ubiquitous protein involved in mRNA processing
[90]. Similar to ZONAB and Cdk4, symplekin is a dual
residency protein which usually accumulates at cell nuclei
but also associates with TJs in polarized epithelial cells
[90]. Interaction of ZONAB with symplekin modulates
the transcriptional activity of ZONAB as evidenced by
alterations in CD1 expression [91].
A direct interaction of ZO-2 with Jun, Fos and C/EBP
(CCAAT/enhancer binding protein) was found to occur
not only in the nucleus but also at the plasma membrane
[92]. Using reporter gene assays, ZO-2 was demonstrated
to suppress gene transcription by binding to the AP-1
transcription factor protein complex [92].
Further, ZO-1 and ZO-2 interact with the dual resi-
dency protein ARVCF (Armadillo repeat gene deleted in
velo-cardio-facial syndrome) [16] ,am e m b e ro ft h ep 1 2 0
catenin family localizing at cadherin-based cell-cell contacts
in conﬂuent epithelial cells. Upon disruption of cell-cell
adhesion, ARVCF is partially translocated to the nucleus by
associating with a PDZ domain of ZO-2. In addition, a C-
terminal region of ZO-3 was shown to interact directly with
p120 catenin, which regulates cadherin-based cell adhesion
and junctional stabilization through Rho signaling [63].
p120 catenin was found to undergo nucleo-cytoplasmic
shuttling and to regulate gene expression by associating
with the methylation-dependent transcriptional repressor
Kaiso [93].
Experimentally induced nuclear accumulation of ZO-
2 in cerebral endothelial cells led to the elevation of
pyruvate kinase M2 (M2PK) protein levels [94]. Although
experimental evidence is still missing, it cannot be excluded
that this eﬀect was elicited by the excessive targeting of
nuclear ZO-2 to the estrogen receptor-binding domain of
SAF-B. M2PK is an isozyme of pyruvate kinase particularly
expressed in proliferating cells, such as embryonic stem
cells and carcinoma cells. A recent report has demonstrated
that M2PK interacts and cooperates with the POU domain
transcription factor Oct-4 which is critically involved in
maintaining the self-renewal capacity of embryonic stem
cells [95]. Although there is a general consensus concerning
the suppressive action of ZO-2 on cell proliferation, it
appearsthattheratiobetweentheamountofZO-2localizing
at TJs and the amount of nuclear ZO-2 adds an additional
variable in the control of epithelial cell proliferation and
diﬀerentiation.
While the nuclear targeting of ZO-1 has well been
described,itsnuclearfunctionshaveremainedunclear.Based
on all experimental evidence so far, it may be concluded that
the nuclear localization of ZO-1 is inversely related to the
extent and/or maturity of cell-cell contacts [79].
7. A Role for ZO Proteinsin Tumor Growth
Some proteins of the MAGUK family behave as tumor sup-
pressors. The homology of ZO proteins with the DrosophilaJournal of Biomedicine and Biotechnology 7
tumour suppressor protein dlgA provided a ﬁrst clue
towards a yet undeﬁned role of ZO proteins in epithelial
cancer development and/or progression. Dlg proteins with
mutations in the PDZ and SH3 domains cause neoplastic
overgrowth of larval imaginal disc epithelial cells [28].
The Drosophila orthologue of ZO-1, Tamou/Polychaetoid,
has been implicated in a signaling pathway which acti-
vates the expression of the helix-loop-helix repressor gene
emc(extramacrochaetae).MutationsinTamou/Polychaetoid
reduce the expression of emc, which causes enlargement of
a proneural cell cluster resulting in extra mechanosensory
organs in the ﬂy [96].
ZO proteins are delocalized or down-regulated in several
types of carcinomas [97]. Further, ZO-1 mutants encoding
only the N terminus including the PDZ domains of ZO-
1 appeared delocalized in the cytoplasm of MDCK cells
and induced a dramatic loss of the epithelial phenotype
of MDCK accompanied by repression of epithelial and
induction of mesenchymal marker genes [98]. Similar results
were obtained by Wittchen et al showing that expression
of exogenous mutated ZO-3 constructs carrying only the
amino terminal half of ZO-3 led to a signiﬁcant delay in
the formation of TJs and AJs and to mislocalization of ZO
proteins and occludin [99].
Epithelial cancers are often related to mutations in the
small GTPase Ras, which mediates cellular signal transduc-
tion regulating cell growth and proliferation [100]. The
peripheral PDZ domain protein AF-6/afadin localizes at
AJ and TJs by directly associating with nectin and JAM
[9, 101]. AF-6 was shown to be targeted by Ras and the
Ras-like GTPase Rap-1 [102, 103]. In polarized epithelial
cells, AF-6/afadin colocalizes with ZO-1 at TJs, and ZO-
1 interacts with the Ras-binding domain of AF-6/afadin.
Overexpression of activated Ras in Rat1 cells resulted in the
perturbation of cell-cell contacts, demonstrating a critical
interplay of Ras, AF-6/afadin and ZO-1 at intercellular
junctions [104].
Junctional proteins carrying PDZ domains were found
to be targeted and degraded by various tumorigenic viruses
[105]. Thereby; PDZ binding motifs located in the viral
proteinareusedtointeractwithPDZdomainsofthetargeted
junctional protein. For example, a conserved 4-amino-acid
PDZ binding motif is present at the carboxy termini of high-
risk human papillomavirus (HPV) E6 proteins [106]. Sim-
ilarly, adenovirus (Ad) type 9 causing exclusively estrogen-
dependent mammary tumors in experimental animals con-
tains a PDZ domain-binding motif required to induce both
cellular transformation in vitro and tumorigenesis in vivo.
The PDZ domain of Ad9 mediates interaction with Dlg1,
PATJ and ZO-2 which promotes disruption and loss of cell
polarity of the infected cells [107].
8. Concluding Remarks
Due to their homology with the tumor suppressor proten
dlgA,zonulaoccludensproteinshavebeenconsideredtoplay
a role in cell growth and proliferation. Since the discovery
of the ﬁrst TJ-associated MAGUK, ZO-1, the importance
of peripheral junctional proteins has become increasingly
recognized. It was considered a major breakthrough when
it was demonstrated that ZO proteins not only exert a scaf-
folding function at the junctional site but are also involved
in intracellular signaling and gene expression. The nuclear
targeting of ZO-1 and ZO-2 has focused much interest on
the nuclear function of ZO proteins. To date, convincing
experimental evidence suggests that ZO proteins are capable
of associating with regulatory molecules (adapter proteins,
signaling molecules, growth factors) thereby modulating the
cell’s progress through the cell cycle. Now, future work must
concentrate on several aspects, including (i) the elucidation
of extra- and intracellular signals which trigger the nuclear
targeting of ZO proteins, (ii) the identiﬁcation of additional
genes the expression of which is up- or downregulated by
the nuclear presence of ZO proteins, and (iii) the role of ZO
proteins in virus-induced cancer.
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